An open-label trial of the selective @entity3840 inhibitor, @entity13586 , in @entity29 -associated peripheral @entity625 and XXXX .

@entity1 @entity13586 @entity625 @entity344 @entity29 @entity1897 @entity158 @entity4841 @entity3840
BACKGROUND: Conventional non-steroidal anti-inflammatory drugs have been associated with an increased risk of exacerbation of @entity29 . AIM: To evaluate, in a prospective, open-label study, the safety and efficacy of a 20-day regimen of the selective @entity3840 inhibitor, @entity13586 , 12.5-25 mg/day, in @entity29 @entity1 with associated @entity1897 and/or @entity625 . METHODS: @entity1 with clinically inactive to mild @entity29 and a joint @entity158 score of at least two points on a scale ranging from zero (none) to four (very poor) were eligible. Response was defined by a decrease of at least two points in the @entity4841 score. RESULTS: Of the 32 @entity1 included, 26 (81%) were treated with @entity13586 , 25 mg/day, and six (19%) with @entity13586 , 12.5 mg/day. In three @entity1 (9%), @entity13586 had to be withdrawn after a few days due to @entity344 which ceased immediately after drug discontinuation. No flare of @entity29 occurred. Thirteen of the 32 @entity1 (41%) were responders and, overall, the @entity4841 score decreased from two to one (P = 0.0001). CONCLUSIONS: This is the first prospective study on the use of a selective @entity3840 inhibitor in @entity29 @entity1 with @entity1897 and/or @entity4841 . The promising safety and efficacy profile warrants further evaluation in controlled trials.
